Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

• Status: Active, not recruiting
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: Female

Summary

Urinary incontinence (UI) is a very common condition affecting women of all ages. The objective of this pilot study is to better understand the urinary microbiome and associated inflammatory markers in blood and urine in women with urgency UI. The study will assess how inflammation may affect response to standard of care anticholinergic medication treatment for urgency urinary incontinence.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: Medical University of Silesia
• Treatments: Cholinergic Antagonists; Oxybutynin; Solifenacin Succinate; Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Postmenopausal (Age ≥ 50) women with UUI

• English speaking

• Willing to take anticholinergics for at least 6 weeks

• Willing to complete UDI-6 and voiding diary at baseline and 6 weeks

• Willing to give urine and blood for study at baseline and 6 weeks

Exclusion Criteria:

• Have taken anticholinergic medication within the last month

• Have taken antibiotics within the last month

• UTI in the last three months

• Neurological disease (eg. Parkinson's disease, MS, etc.)

• Immunological deficiencies

• History of STDs

• Lack of consent

• Not ambulatory (e.g. uses a wheelchair)